Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

F. Kelley, Colleen; Acevedo-Quiñones, Maribel; L. Agwu, Allison; Avihingsanon, Anchalee; Benson, Paul; Blumenthal, Jill; Brinson, Cynthia; Brites, Carlos; Cahn, Pedro; D Cantos, Valeria; L. Clark, Jesse; E. Clement, Meredith; Creticos, Cathy; Crofoot, Gordon; Sobhie Diaz, Ricardo; Doblecki‐Lewis, Susanne; A. Gallardo-Cartagena, Jorge; H. Gaur, Aditya; Grinsztejn, Beatriz; Hassler, Shawn; Hinojosa, Juan; Hodge, Theo; Kaplan, Richard; Lacerda, Marcus; LaMarca, Anthony; Losso, Marcelo; Valdez Madruga, José; H. Mayer, Kenneth; Mills, Anthony; Mounzer, Karam; Ndlovu, Nkosiphile; Novák, Richard; Perez Rios, Alma; Phanuphak, Nittaya; Ramgopal, Moti; Ruane, Peter; Sánchez, Jorge; Santos, Breno; Schine, Patric; Schreibman, Tanya; Spencer, LaShonda; T. Van Gerwen, Olivia; Vasconcelos, Ricardo; Gabriel Vasquez, Jose; Zwane, Zwelethu; Cox, Stephanie; Deaton, Chris; Ebrahimi, Ramin; Wong, Pamela; Singh, Renu; B. Brown, Lillian; C Carter, Christoph; Das, Moupali; M. Baeten, Jared; Ogbuagu, Onyema

doi:10.1056/nejmoa2411858

Public

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Published in New England Journal of Medicine • Nov 27, 2024

Authors:

Colleen F. Kelley

Maribel Acevedo-Quiñones

Allison L. Agwu

Abstract

BACKGROUND: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of human immunodeficiency virus (HIV) infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbin...

Subject

Medicine

Incidence (geometry)

Confidence interval

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!